BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis

Detailed price information for Bionxt Solutions Inc. (BNXT-CN) from The Globe and Mail including charting and trades.
Drug Target Review

The map and compass: integrating BD&L early to de-risk drug discovery

Explore the role of BD&L in R&D decision-making. Understand its impact on funding and market intelligence for scientists.

Design Therapeutics Highlights GeneTAC Pipeline, FA Data Timeline and DM1 Dosing Plans at Oppenheimer Conference

Design Therapeutics (NASDAQ:DSGN) outlined progress across three clinical-stage programs and discussed upcoming catalysts during an Oppenheimer healthcare conference presentation led by CEO Pratik ...
Le Lézard

Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis

Blueprint Medicines, a Sanofi company, today announced AYVAKIT® (avapritinib) data showing clinically meaningful outcomes and a well-tolerated long-term safety profile in patients with indolent ...
Investopedia

Black-Scholes Model: What It Is, How It Works, and the Options Formula

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
AgWeb

Roundup at a Crossroads: Bayer Lays Out Short-Term Window for Finding a Way Forward with Glyphosate

Seven years ago, two events set forth a domino effect culminating in Bayer leaders having a potential “tough decision” of whether or not the company will continue to manufacture its legacy herbicide ...